127 related articles for article (PubMed ID: 15086486)
1. Plasma aldosterone concentration in the patient with diabetes mellitus.
Hollenberg NK; Stevanovic R; Agarwal A; Lansang MC; Price DA; Laffel LM; Williams GH; Fisher ND
Kidney Int; 2004 Apr; 65(4):1435-9. PubMed ID: 15086486
[TBL] [Abstract][Full Text] [Related]
2. The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus.
Price DA; De'Oliveira JM; Fisher ND; Williams GH; Hollenberg NK
Am J Hypertens; 1999 Apr; 12(4 Pt 1):348-55. PubMed ID: 10232494
[TBL] [Abstract][Full Text] [Related]
3. Relationship between urinary sodium excretion and serum aldosterone in patients with diabetes in the presence and absence of modifiers of the renin-angiotensin-aldosterone system.
Libianto R; Jerums G; Lam Q; Chen A; Baqar S; Pyrlis F; Macisaac RJ; Moran J; Ekinci EI
Clin Sci (Lond); 2014 Jan; 126(2):147-54. PubMed ID: 23875766
[TBL] [Abstract][Full Text] [Related]
4. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
Yoneda T; Takeda Y; Usukura M; Oda N; Takata H; Yamamoto Y; Karashima S; Yamagishi M
Am J Hypertens; 2007 Dec; 20(12):1329-33. PubMed ID: 18047925
[TBL] [Abstract][Full Text] [Related]
5. Low plasma aldosterone despite normal plasma renin activity in uncomplicated type 1 diabetes mellitus: effects of RAAS stimulation.
Luik PT; Kerstens MN; Hoogenberg K; Navis GJ; Dullaart RP
Eur J Clin Invest; 2003 Sep; 33(9):787-93. PubMed ID: 12925038
[TBL] [Abstract][Full Text] [Related]
6. Short-term dietary salt supplementation blunts telmisartan induced increases in plasma renin activity in hypertensive patients with type 2 diabetes mellitus.
Chen AX; Jerums G; Baqar S; Lambert E; Somarajah G; Thomas G; O'Callaghan C; MacIsaac RJ; Ekinci EI
Clin Sci (Lond); 2015 Sep; 129(5):415-22. PubMed ID: 25849646
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
[TBL] [Abstract][Full Text] [Related]
8. Reduced glomerular angiotensin II receptor density in diabetes mellitus in the rat: time course and mechanism.
Wilkes BM
Endocrinology; 1987 Apr; 120(4):1291-8. PubMed ID: 3549258
[TBL] [Abstract][Full Text] [Related]
9. Renin release in response to Renin system blockade: activation of the Renin system in type 1 diabetes mellitus.
Stevanovic RD; Price DA; Lansang MC; Fisher ND; Laffel LM; Hollenberg NK
J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):78-83. PubMed ID: 16470486
[TBL] [Abstract][Full Text] [Related]
10. The renin-angiotensin-aldosterone system in decompensated cirrhosis: its activity in relation to sodium balance.
Sellars L; Shore AC; Mott V; Wilkinson R
Q J Med; 1985 Aug; 56(220):485-96. PubMed ID: 3901077
[TBL] [Abstract][Full Text] [Related]
11. Effects of sodium intake on plasma potassium and renin angiotensin aldosterone system in conscious dogs.
Kjolby MJ; Kompanowska-Jezierska E; Wamberg S; Bie P
Acta Physiol Scand; 2005 Jul; 184(3):225-34. PubMed ID: 15954990
[TBL] [Abstract][Full Text] [Related]
12. Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus.
Lansang MC; Price DA; Laffel LM; Osei SY; Fisher ND; Erani D; Hollenberg NK
Kidney Int; 2001 Apr; 59(4):1432-8. PubMed ID: 11260405
[TBL] [Abstract][Full Text] [Related]
13. Blunted suppression of plasma renin activity in diabetes.
Gordon MS; Price DA; Hollenberg NK
J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):252-6. PubMed ID: 11881033
[TBL] [Abstract][Full Text] [Related]
14. Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man. Dopaminergic control of aldosterone.
Carey RM; Thorner MO; Ortt EM
J Clin Invest; 1979 Apr; 63(4):727-35. PubMed ID: 438333
[TBL] [Abstract][Full Text] [Related]
15. Adrenal renin-angiotensin-aldosterone system in streptozotocin-diabetic rats.
Nakayama T; Izumi Y; Soma M; Kanmatsuse K
Horm Metab Res; 1998 Jan; 30(1):12-5. PubMed ID: 9503033
[TBL] [Abstract][Full Text] [Related]
16. Reduced plasma aldosterone concentrations in randomly selected patients with insulin-dependent diabetes mellitus.
Cronin CC; Barry D; Crowley B; Ferriss JB
Diabet Med; 1995 Sep; 12(9):809-15. PubMed ID: 8542742
[TBL] [Abstract][Full Text] [Related]
17. Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension.
Bauer IH; Reams GP; Wu Z; Lau-Sieckman A
J Hum Hypertens; 1995 Apr; 9(4):237-43. PubMed ID: 7595905
[TBL] [Abstract][Full Text] [Related]
18. Potassim-aldosterone-renin interrelationships.
Himathongkam T; Dluhy RG; Williams GH
J Clin Endocrinol Metab; 1975 Jul; 41(1):153-9. PubMed ID: 1167307
[TBL] [Abstract][Full Text] [Related]
19. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
[TBL] [Abstract][Full Text] [Related]
20. Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney.
van den Heuvel M; Batenburg WW; Jainandunsing S; Garrelds IM; van Gool JM; Feelders RA; van den Meiracker AH; Danser AH
J Hypertens; 2011 Nov; 29(11):2147-55. PubMed ID: 21941204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
